• 1
    Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 25560.
  • 2
    Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15: 1699708.
  • 3
    Menor C, Fueyo JA, Escribano O, et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography. Comparison with the radiochemical method. Ther Drug Monit 2001; 23: 53641.
  • 4
    Bermejo F, López San Román AL, Hinojosa J, Castro L, Jurado C, Gómez-Belda AB. Infliximab induces clinical, endoscopical and histological response in refractory ulcerative colitis. Rev Esp Enferm Dig 2004; 96: 94101.
  • 5
    Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 62730.
  • 6
    Caprilli R, Carratu’ R, Babbini M. A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopatic proctocolitis. Dig Dis 1975; 20: 11520.
  • 7
    Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 969.
  • 8
    Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982; 284: 12912.
  • 9
    Present DH, Chapman ML, Rubin PH. Efficacy of 6-mercaptopurine (6-MP) in refractory ulcerative colitis. Gastroenterology 1988; 94: A359.
  • 10
    Steinhart AH, Baker JP, Brzezinski A, Prokipchuk EJ. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 1990; 12: 2715.
  • 11
    Lobo AJ, Foster PN, Burke DA, Johnston D, Axon ATR. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990; 33: 3747.
  • 12
    Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 71722.
  • 13
    Bianchi Porro G, Petrillo M, Ardizzone S, Desideri S. Azathioprine in the treatment of ulcerative colitis. J Clin Gastroenterol 1991; 13: 1134.
  • 14
    Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 202.
  • 15
    George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 17114.
  • 16
    Ardizzone S, Molteni F, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25: 3303.
  • 17
    Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 122733.
  • 18
    Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 2000; 62: 24954.
  • 19
    Kull E, Beau P. Efficacité comparée de l'azathioprine dans la rectolite hémorragique et dans la maladie de Crohn. Gastroenterol Clin Biol 2001; 25: 36771.
  • 20
    Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 2003; 22: 7981.
  • 21
    Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 17519.
  • 22
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 4859.
  • 23
    Pearson DC, May GR, Fick CK, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Int Med 1995; 122: 13242.
  • 24
    Binderow SR, Wexner SD. Current surgical therapy for mucosal ulcerative colitis. Dis Colon Rectum 1994; 37: 61024.
  • 25
    Present DG, Meltzer SJ, Krumholz MP, Wolke A, Korelitz B. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 6419.
  • 26
    Singleton JW, Law DH, Kelley ML, Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 87082.
  • 27
    Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 102530.
  • 28
    Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293301.
  • 29
    Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med Clin (Barc) 2003; 121: 15.
  • 30
    Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 1937.
  • 31
    Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 454: 18103.
  • 32
    Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14: 15615.
  • 33
    McGovern DPB, Travis SPL, Duley J, Shobowale-Bakre ElM, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122: 8389.
  • 34
    Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135: 25662.
  • 35
    Thomas CW Jr, Lowry PW, Franklin CL, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003; 9: 23745.
  • 36
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.